title: In vitro effects of mitomycin C on the proliferation of the non-small-cell lung cancer line A549.
abstract: Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer in the United States. Chemotherapy prolongs survival among patients with advanced disease, but at the cost of clinically significant adverse effects. As a novel promising oncotherapy method, induced differentiation by mitomycin C has been applied for NSCLC therapy at recent year. In this study, the molecular mechanism of differentiation interruption by mitomycin C in the NSCLC line A549 was investigated. High dosage of mitomycin C (300 µM) could significantly inhibit cell proliferation (P < 0.05) by 48.39 ± 3.32% (P < 0.05), under which cell shrinkage and disruption were observed. Flow cytometry assay showed that the proportion of G1/G0 cells significantly increased, while that of S and G2/M cells significantly decreased after treatment of mitomycin C (10 or 300 µM) for 24 h. These results indicated that cell arrest by mitomycin C appeared. Additionally, up-regulation of retinoblastoma (Rb) gene by low concentration of mitomycin C (10 µM) was detected using immunohistochemistry (IHC) and Western blot assay, indicating a role in the regulation of cell cycle inhibition of this cell line.
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: An
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Han
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Yubing
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Duolu
authors.initials: D
authors.lastname: Li
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Zujiang
authors.initials: Z
authors.lastname: Yu
authors.affiliation: Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital Boston 02114, USA.
authors.forename: Zhenfeng
authors.initials: Z
authors.lastname: Duan
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, China.
authors.forename: Quancheng
authors.initials: Q
authors.lastname: Kan
keywords: Mitomycin C; cell cycle; differentiation; non-small-cell lung cancer (NSCLC); retinoblastoma (Rb) gene